Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Debt Ratio (2017 - 2025)

Historic Debt Ratio for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to 0.29.

  • Innate Pharma's Debt Ratio rose 2410.24% to 0.29 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.29, marking a year-over-year increase of 2410.24%. This contributed to the annual value of 0.28 for FY2024, which is 2255.84% up from last year.
  • Per Innate Pharma's latest filing, its Debt Ratio stood at 0.29 for Q2 2025, which was up 2410.24% from 0.28 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Debt Ratio ranged from a high of 0.29 in Q2 2025 and a low of 0.06 during Q2 2021
  • Its 5-year average for Debt Ratio is 0.2, with a median of 0.2 in 2023.
  • Examining YoY changes over the last 5 years, Innate Pharma's Debt Ratio showed a top increase of 16644.31% in 2021 and a maximum decrease of 972.45% in 2021.
  • Innate Pharma's Debt Ratio (Quarter) stood at 0.17 in 2021, then increased by 22.87% to 0.2 in 2022, then grew by 12.03% to 0.23 in 2023, then increased by 22.56% to 0.28 in 2024, then grew by 4.21% to 0.29 in 2025.
  • Its Debt Ratio was 0.29 in Q2 2025, compared to 0.28 in Q4 2024 and 0.23 in Q2 2024.